vs
Side-by-side financial comparison of Core Laboratories Inc. (CLB) and iRhythm Holdings, Inc. (IRTC). Click either name above to swap in a different company.
iRhythm Holdings, Inc. is the larger business by last-quarter revenue ($208.9M vs $121.8M, roughly 1.7× Core Laboratories Inc.). Core Laboratories Inc. runs the higher net margin — 4.2% vs 2.7%, a 1.5% gap on every dollar of revenue. On growth, iRhythm Holdings, Inc. posted the faster year-over-year revenue change (27.1% vs -1.4%). iRhythm Holdings, Inc. produced more free cash flow last quarter ($14.5M vs $517.0K). Over the past eight quarters, iRhythm Holdings, Inc.'s revenue compounded faster (25.8% CAGR vs -3.4%).
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.
iRhythm Holdings is a digital healthcare company focused on cardiac care, developing and commercializing wearable ambulatory heart monitoring devices paired with AI-powered analytical tools. It primarily serves healthcare providers and patients across the United States, helping to detect undiagnosed arrhythmias such as atrial fibrillation through convenient long-term heart rhythm tracking that delivers actionable clinical insights.
CLB vs IRTC — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $121.8M | $208.9M |
| Net Profit | $5.1M | $5.6M |
| Gross Margin | — | 70.9% |
| Operating Margin | 1.5% | 1.1% |
| Net Margin | 4.2% | 2.7% |
| Revenue YoY | -1.4% | 27.1% |
| Net Profit YoY | — | 518.5% |
| EPS (diluted) | $0.11 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $121.8M | — | ||
| Q4 25 | $138.3M | $208.9M | ||
| Q3 25 | $134.5M | $192.9M | ||
| Q2 25 | $130.2M | $186.7M | ||
| Q1 25 | $123.6M | $158.7M | ||
| Q4 24 | $129.2M | $164.3M | ||
| Q3 24 | $134.4M | $147.5M | ||
| Q2 24 | $130.6M | $148.0M |
| Q1 26 | $5.1M | — | ||
| Q4 25 | $4.9M | $5.6M | ||
| Q3 25 | $14.2M | $-5.2M | ||
| Q2 25 | $10.6M | $-14.2M | ||
| Q1 25 | $-154.0K | $-30.7M | ||
| Q4 24 | $7.4M | $-1.3M | ||
| Q3 24 | $11.7M | $-46.2M | ||
| Q2 24 | $9.0M | $-20.1M |
| Q1 26 | — | — | ||
| Q4 25 | 20.8% | 70.9% | ||
| Q3 25 | 22.0% | 71.1% | ||
| Q2 25 | 20.3% | 71.2% | ||
| Q1 25 | 19.5% | 68.8% | ||
| Q4 24 | 17.8% | 70.0% | ||
| Q3 24 | 20.5% | 68.8% | ||
| Q2 24 | 21.2% | 69.9% |
| Q1 26 | 1.5% | — | ||
| Q4 25 | 11.5% | 1.1% | ||
| Q3 25 | 15.6% | -4.4% | ||
| Q2 25 | 11.7% | -10.0% | ||
| Q1 25 | 3.6% | -20.5% | ||
| Q4 24 | 11.0% | -2.5% | ||
| Q3 24 | 14.7% | -34.1% | ||
| Q2 24 | 12.3% | -15.5% |
| Q1 26 | 4.2% | — | ||
| Q4 25 | 3.6% | 2.7% | ||
| Q3 25 | 10.6% | -2.7% | ||
| Q2 25 | 8.2% | -7.6% | ||
| Q1 25 | -0.1% | -19.3% | ||
| Q4 24 | 5.7% | -0.8% | ||
| Q3 24 | 8.7% | -31.3% | ||
| Q2 24 | 6.9% | -13.6% |
| Q1 26 | $0.11 | — | ||
| Q4 25 | $0.11 | $0.18 | ||
| Q3 25 | $0.30 | $-0.16 | ||
| Q2 25 | $0.22 | $-0.44 | ||
| Q1 25 | $0.00 | $-0.97 | ||
| Q4 24 | $0.15 | $-0.03 | ||
| Q3 24 | $0.25 | $-1.48 | ||
| Q2 24 | $0.19 | $-0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.8M | $583.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $275.1M | $152.7M |
| Total Assets | $587.7M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $22.8M | — | ||
| Q4 25 | $22.7M | $583.8M | ||
| Q3 25 | $25.6M | $565.2M | ||
| Q2 25 | $31.2M | $545.5M | ||
| Q1 25 | $22.1M | $520.6M | ||
| Q4 24 | $19.2M | $535.6M | ||
| Q3 24 | $21.5M | $522.0M | ||
| Q2 24 | $17.7M | $561.5M |
| Q1 26 | — | — | ||
| Q4 25 | $110.3M | — | ||
| Q3 25 | $114.1M | — | ||
| Q2 25 | $124.6M | — | ||
| Q1 25 | $124.4M | — | ||
| Q4 24 | $126.1M | — | ||
| Q3 24 | $139.9M | — | ||
| Q2 24 | $147.6M | — |
| Q1 26 | $275.1M | — | ||
| Q4 25 | $266.0M | $152.7M | ||
| Q3 25 | $271.3M | $121.9M | ||
| Q2 25 | $261.3M | $103.7M | ||
| Q1 25 | $253.4M | $86.7M | ||
| Q4 24 | $246.6M | $90.9M | ||
| Q3 24 | $250.7M | $71.8M | ||
| Q2 24 | $240.3M | $99.2M |
| Q1 26 | $587.7M | — | ||
| Q4 25 | $584.0M | $1.0B | ||
| Q3 25 | $591.4M | $995.2M | ||
| Q2 25 | $602.1M | $964.0M | ||
| Q1 25 | $591.5M | $926.1M | ||
| Q4 24 | $585.1M | $931.4M | ||
| Q3 24 | $600.5M | $909.7M | ||
| Q2 24 | $597.8M | $919.2M |
| Q1 26 | — | — | ||
| Q4 25 | 0.41× | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.56× | — | ||
| Q2 24 | 0.61× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.0M | $26.2M |
| Free Cash FlowOCF − Capex | $517.0K | $14.5M |
| FCF MarginFCF / Revenue | 0.4% | 6.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | 0.77× | 4.70× |
| TTM Free Cash FlowTrailing 4 quarters | $22.5M | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $4.0M | — | ||
| Q4 25 | $7.9M | $26.2M | ||
| Q3 25 | $8.5M | $34.9M | ||
| Q2 25 | $13.9M | $27.7M | ||
| Q1 25 | $6.7M | $-7.9M | ||
| Q4 24 | $20.6M | $19.2M | ||
| Q3 24 | $13.1M | $24.3M | ||
| Q2 24 | $17.1M | $11.8M |
| Q1 26 | $517.0K | — | ||
| Q4 25 | $5.0M | $14.5M | ||
| Q3 25 | $6.5M | $20.1M | ||
| Q2 25 | $10.4M | $17.3M | ||
| Q1 25 | $3.9M | $-17.3M | ||
| Q4 24 | $17.4M | $12.4M | ||
| Q3 24 | $10.4M | $15.5M | ||
| Q2 24 | $14.3M | $3.4M |
| Q1 26 | 0.4% | — | ||
| Q4 25 | 3.6% | 6.9% | ||
| Q3 25 | 4.8% | 10.4% | ||
| Q2 25 | 8.0% | 9.3% | ||
| Q1 25 | 3.1% | -10.9% | ||
| Q4 24 | 13.4% | 7.5% | ||
| Q3 24 | 7.7% | 10.5% | ||
| Q2 24 | 10.9% | 2.3% |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 5.6% | ||
| Q3 25 | 1.5% | 7.7% | ||
| Q2 25 | 2.7% | 5.6% | ||
| Q1 25 | 2.3% | 5.9% | ||
| Q4 24 | 2.5% | 4.2% | ||
| Q3 24 | 2.0% | 6.0% | ||
| Q2 24 | 2.2% | 5.7% |
| Q1 26 | 0.77× | — | ||
| Q4 25 | 1.61× | 4.70× | ||
| Q3 25 | 0.60× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.78× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.90× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLB
Segment breakdown not available.
IRTC
| Commercial Payors | $111.7M | 53% |
| Centers For Medicare And Medicaid | $49.2M | 24% |
| Healthcare Institutions | $34.3M | 16% |
| Non Contracted Third Party Payors | $13.7M | 7% |
